Inhibrx Reports Q4 Revenue of $0, Cash Balance at $124.2M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2026
0mins
Should l Buy INBX?
Reports Q4 revenue $0 vs. $100K last year. As of December 31, 2025, Inhibrx had cash and cash equivalents of $124.2M.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INBX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INBX
About INBX
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inhibrx Biosciences Reports 2025 Financial Results
- Financial Overview: As of December 31, 2025, Inhibrx reported cash and cash equivalents of $124.2 million, indicating a relatively healthy liquidity position post-transaction with Sanofi, despite facing a net loss of $140.1 million.
- R&D Expense Analysis: Inhibrx's R&D expenses reached $113.1 million in 2025, significantly down from $203.7 million in 2024, reflecting the company's strategic shift towards optimizing resource allocation in response to market challenges.
- Operating Loss Situation: The company reported an operating loss of $135 million in 2025, and while revenues increased, high operational costs continue to exert pressure on financial performance, impacting investor confidence.
- Future Outlook and Plans: Inhibrx plans to submit a Biologics License Application to the FDA in Q2 2026 and expects to announce clinical trial data for ozekibart and INBRX-106, which, if successful, could significantly enhance the company's market position.
See More
Inhibrx Biosciences Reports Q4 Earnings Miss
- Earnings Report Miss: Inhibrx Biosciences reported a Q4 GAAP EPS of -$2.11, missing expectations by $0.03, indicating ongoing challenges in profitability that could impact investor confidence.
- Cash Position: As of December 31, 2025, Inhibrx had cash and cash equivalents totaling $124.2 million, which, while providing some liquidity, raises concerns about the efficiency of fund utilization and future financing needs.
- Loan Agreement Amendment: On March 18, 2026, the company entered into the First Amendment to the Loan and Security Agreement with Oxford Finance, LLC, securing gross proceeds of $75 million, which will provide short-term funding support and alleviate financial pressure.
- Market Outlook: Despite financial challenges, Inhibrx is actively pursuing treatments for chondrosarcoma and other targeted indications, with future R&D advancements potentially offering new growth opportunities for the company.
See More
Inhibrx Biosciences Options Risk Analysis
- Options Selling Risk: Selling puts on Inhibrx Biosciences does not provide the same upside potential as owning shares, as the put seller only acquires shares if the contract is exercised, highlighting the inherent risks of options trading.
- Exercise Condition Analysis: The put seller will only own shares at a cost basis of $42.00 if Inhibrx's stock declines by 31.7% and the contract is exercised, illustrating the complexity and potential losses associated with exercising options.
- Annualized Yield: The only upside for the put seller comes from the premium collected, yielding an annualized return of 16.7%, indicating that the risk-reward balance must be carefully evaluated under current market conditions.
- Volatility Consideration: With a trailing twelve-month volatility of 95% for Inhibrx, combining this with fundamental analysis can assist investors in determining whether selling the $50 strike put represents a worthwhile risk to take.
See More
Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments
- Stock Performance: Palvella Therapeutics saw its stock surge from $25 on March 10, 2025, to a 52-week high of $114.69 on December 22, 2025, reflecting strong market potential in rare disease treatments.
- Product Development: Its lead product, QTORIN rapamycin, targets microcystic lymphatic malformations and other rare diseases, with potential FDA approval expected to unlock a multi-billion-dollar market opportunity, further solidifying the company's position in the biopharmaceutical sector.
- Acquisition Activity: Cidara Therapeutics agreed to be acquired by Merck for $221.50 per share, totaling approximately $9.2 billion, with the deal expected to close in Q1 2026, highlighting major pharmaceutical interest in innovative therapies.
- Clinical Progress: Celcuity's Gedatolisib submitted a New Drug Application to the FDA in November 2025 for HR+, HER2- advanced breast cancer, which, if approved, would significantly enhance its competitive edge in the oncology market.
See More
Inhibrx Stock Surges 150% Post Ozekibart Trial Results but Faces Structural Risks
- Stock Surge: Inhibrx's stock price skyrocketed over 150% shortly after reporting positive topline results from its Ozekibart (INBRX-109) registrational trial in October 2025, indicating strong market confidence in its product.
- Cycle Analysis: Currently in Phase 2 of the 18-phase Adhishthana cycle, Inhibrx's stock is deviating from expected behavior, as it should typically consolidate or correct during this phase, raising concerns about potential instability ahead.
- Historical Lessons: Similar to Lamb Weston, where premature rallies led to over 60% corrections upon entering the Buddhi phase, investors should remain cautious to avoid significant losses.
- Investor Outlook: While the stock may continue to rise in the short term, the misalignment with the natural rhythm of the Adhishthana cycle suggests that investors should carefully assess potential risks before chasing the stock at current levels.
See More
Inhibrx Progresses with INBRX-106 and Ozekibart Programs, Anticipates Major Milestones in the Coming Year
INBRX-106 Development: Inhibrx Biosciences is advancing its INBRX-106 program, which activates the OX40 protein to enhance immune response against cancer, currently being tested in combination with Merck's Keytruda for head and neck and non-small cell lung cancers.
Clinical Trials Status: A phase 2/3 trial for INBRX-106 in head and neck cancer is ongoing, with 46 out of 60 patients enrolled, while a phase 1/2 trial for non-small cell lung cancer has completed enrollment of 34 patients.
Ozekibart Trials: Ozekibart is under investigation in phase 1/2 trials for advanced colorectal cancer and Ewing sarcoma, with expected data maturity for colorectal cancer in Q2 2026 and plans for FDA discussions regarding accelerated approval for Ewing sarcoma.
Market Performance: Inhibrx's stock closed at $81.57, reflecting a 7.03% increase, indicating positive market sentiment amidst ongoing clinical developments.
See More
Inhibrx Biosciences Reports 2025 Financial Results
- Financial Overview: As of December 31, 2025, Inhibrx reported cash and cash equivalents of $124.2 million, indicating a relatively healthy liquidity position post-transaction with Sanofi, despite facing a net loss of $140.1 million.
- R&D Expense Analysis: Inhibrx's R&D expenses reached $113.1 million in 2025, significantly down from $203.7 million in 2024, reflecting the company's strategic shift towards optimizing resource allocation in response to market challenges.
- Operating Loss Situation: The company reported an operating loss of $135 million in 2025, and while revenues increased, high operational costs continue to exert pressure on financial performance, impacting investor confidence.
- Future Outlook and Plans: Inhibrx plans to submit a Biologics License Application to the FDA in Q2 2026 and expects to announce clinical trial data for ozekibart and INBRX-106, which, if successful, could significantly enhance the company's market position.
See More
Inhibrx Biosciences Reports Q4 Earnings Miss
- Earnings Report Miss: Inhibrx Biosciences reported a Q4 GAAP EPS of -$2.11, missing expectations by $0.03, indicating ongoing challenges in profitability that could impact investor confidence.
- Cash Position: As of December 31, 2025, Inhibrx had cash and cash equivalents totaling $124.2 million, which, while providing some liquidity, raises concerns about the efficiency of fund utilization and future financing needs.
- Loan Agreement Amendment: On March 18, 2026, the company entered into the First Amendment to the Loan and Security Agreement with Oxford Finance, LLC, securing gross proceeds of $75 million, which will provide short-term funding support and alleviate financial pressure.
- Market Outlook: Despite financial challenges, Inhibrx is actively pursuing treatments for chondrosarcoma and other targeted indications, with future R&D advancements potentially offering new growth opportunities for the company.
See More
Inhibrx Biosciences Options Risk Analysis
- Options Selling Risk: Selling puts on Inhibrx Biosciences does not provide the same upside potential as owning shares, as the put seller only acquires shares if the contract is exercised, highlighting the inherent risks of options trading.
- Exercise Condition Analysis: The put seller will only own shares at a cost basis of $42.00 if Inhibrx's stock declines by 31.7% and the contract is exercised, illustrating the complexity and potential losses associated with exercising options.
- Annualized Yield: The only upside for the put seller comes from the premium collected, yielding an annualized return of 16.7%, indicating that the risk-reward balance must be carefully evaluated under current market conditions.
- Volatility Consideration: With a trailing twelve-month volatility of 95% for Inhibrx, combining this with fundamental analysis can assist investors in determining whether selling the $50 strike put represents a worthwhile risk to take.
See More
Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments
- Stock Performance: Palvella Therapeutics saw its stock surge from $25 on March 10, 2025, to a 52-week high of $114.69 on December 22, 2025, reflecting strong market potential in rare disease treatments.
- Product Development: Its lead product, QTORIN rapamycin, targets microcystic lymphatic malformations and other rare diseases, with potential FDA approval expected to unlock a multi-billion-dollar market opportunity, further solidifying the company's position in the biopharmaceutical sector.
- Acquisition Activity: Cidara Therapeutics agreed to be acquired by Merck for $221.50 per share, totaling approximately $9.2 billion, with the deal expected to close in Q1 2026, highlighting major pharmaceutical interest in innovative therapies.
- Clinical Progress: Celcuity's Gedatolisib submitted a New Drug Application to the FDA in November 2025 for HR+, HER2- advanced breast cancer, which, if approved, would significantly enhance its competitive edge in the oncology market.
See More
Inhibrx Stock Surges 150% Post Ozekibart Trial Results but Faces Structural Risks
- Stock Surge: Inhibrx's stock price skyrocketed over 150% shortly after reporting positive topline results from its Ozekibart (INBRX-109) registrational trial in October 2025, indicating strong market confidence in its product.
- Cycle Analysis: Currently in Phase 2 of the 18-phase Adhishthana cycle, Inhibrx's stock is deviating from expected behavior, as it should typically consolidate or correct during this phase, raising concerns about potential instability ahead.
- Historical Lessons: Similar to Lamb Weston, where premature rallies led to over 60% corrections upon entering the Buddhi phase, investors should remain cautious to avoid significant losses.
- Investor Outlook: While the stock may continue to rise in the short term, the misalignment with the natural rhythm of the Adhishthana cycle suggests that investors should carefully assess potential risks before chasing the stock at current levels.
See More
Inhibrx Progresses with INBRX-106 and Ozekibart Programs, Anticipates Major Milestones in the Coming Year
INBRX-106 Development: Inhibrx Biosciences is advancing its INBRX-106 program, which activates the OX40 protein to enhance immune response against cancer, currently being tested in combination with Merck's Keytruda for head and neck and non-small cell lung cancers.
Clinical Trials Status: A phase 2/3 trial for INBRX-106 in head and neck cancer is ongoing, with 46 out of 60 patients enrolled, while a phase 1/2 trial for non-small cell lung cancer has completed enrollment of 34 patients.
Ozekibart Trials: Ozekibart is under investigation in phase 1/2 trials for advanced colorectal cancer and Ewing sarcoma, with expected data maturity for colorectal cancer in Q2 2026 and plans for FDA discussions regarding accelerated approval for Ewing sarcoma.
Market Performance: Inhibrx's stock closed at $81.57, reflecting a 7.03% increase, indicating positive market sentiment amidst ongoing clinical developments.
See More
